GH secretagogue · Pentapeptide
Ipamorelin
Selective GHS-R agonist · Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Quick facts
Formula
C38H49N9O5
Weight
711.85 g/mol
Class
Aib-His-D-2-Nal-D-Phe-Lys-NH₂
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide developed as a selective growth hormone secretagogue. Unlike earlier GHRPs, research has shown minimal effect on cortisol, prolactin, or ACTH release.
Research mechanism
Published research has examined the following mechanisms:
- GHS-R1a agonism — selective binding on pituitary somatotrophs, calcium signaling and GH release in animal models.
- Selectivity — negligible activation of cortisol/ACTH/LH/FSH pathways.
- Pulsatile release — pattern more resembling endogenous GH pulses.
- Synergy with GHRH analogs — combined administration examined in animal models.
Note: All mechanism data is from published research. Not FDA-approved for human use.
Physical properties & handling
Reconstitute 5 mg with 1.0 mL bacteriostatic water (5 mg/mL). Refrigerate; use within 28 days.
Quality specifications (Broceutical Ipamorelin)
- Purity: 99.3% typical
- Identity: LC-MS/MS confirmed
- Endotoxin: <1 EU/mg
- Form: Lyophilized powder
Published research references
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552-61. PubMed PMID: 9849822
- PubMed literature search https://pubmed.ncbi.nlm.nih.gov/?term=ipamorelin
Broceutical does not endorse or make claims from the above research.
Research Use Only
Ipamorelin supplied by Broceutical is a research chemical for in-vitro laboratory research only. Not FDA-approved for human or veterinary use.